Taysha Gene Therapies (TSHA) Net Margin (2023 - 2025)
Taysha Gene Therapies (TSHA) posted Net Margin of 2297.94% for Q4 2025, down 69.77% sequentially from 1353.58% in Q2 2025, and down 136891.0% YoY from N/an in Q4 2024.
Powered by 
Analysis
Taysha Gene Therapies (TSHA) Net Margin (2023 - 2025) Analysis & Trends
Taysha Gene Therapies has reported Net Margin for 3 years, with the latest figure at 2297.94% in Q4 2025.
- Quarterly Net Margin fell 136891.0% year-over-year to 2297.94% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 4061.16% (down 286008.0% YoY) and the FY2025 annual result came in at 1981.73%, down 91011.0% from the prior year.
- Net Margin eased to 2297.94% in Q4 2025 per TSHA's latest filing, from 1353.58% in the prior quarter.
- Over five years, Net Margin peaked at 1324.67% in Q4 2023 and troughed at 2467.07% in Q3 2023.
- A 3-year average of 1097.69% and a median of 1027.06% in 2023 frame the typical range for Net Margin.
- The widest YoY moves for Net Margin: up 103955 bps in 2024, down 225370 bps in 2024.
- Over 3 years, Net Margin stood at 1324.67% in 2023, then tumbled by 170 bps to 929.03% in 2024, then plunged by 147 bps to 2297.94% in 2025.
- According to Business Quant data, Net Margin over the past three periods registered 2297.94%, 1353.58%, and 935.23% for Q4 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Taysha Gene Therapies | 2.06 Bn | 2.06 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -507.77% |
| Jun 30, 2025 | -1,353.58% |
| Mar 31, 2025 | -935.23% |
| Dec 31, 2024 | -929.03% |
| Sep 30, 2024 | -1,427.52% |
| Jun 30, 2024 | -1,882.01% |
| Mar 31, 2024 | -705.39% |
| Dec 31, 2023 | 1,324.67% |
| Sep 30, 2023 | -2,467.07% |
| Jun 30, 2023 | -1,027.06% |
| Mar 31, 2023 | -374.46% |